Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa
المؤلفون المشاركون
Poewe, Werner
Zadikoff, Cindy
Boyd, James T.
Bergmann, Lars
Ijacu, Horia
Kukreja, Pavnit
Robieson, Weining Z.
Benesh, Janet
Antonini, Angelo
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-02-13
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Background.
Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson’s disease (PD).
This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients.
Methods.
Data were collected from several prospective, phase III clinical studies and an observational registry.
The phase III program (N = 412) included four multicenter studies: a 12-week, randomized, double-blind study and three open-label studies extending ≥12 months.
GLORIA (N = 375) was a 24-month, multicountry, observational registry.
LCIG safety (adverse effects (AEs)/adverse drug reactions (ADRs)) and efficacy (modified Unified Parkinson’s Disease Rating Scale (UPDRS) part IV item 32 and 39 scores for “On” time with dyskinesia and “Off” time) were assessed in patients who received ≥2000 mg/day vs <2000 mg/day LCIG.
Results.
A total of 72 of 412 (17.5%) patients required dosages ≥2000 mg/day LCIG in the phase III program and 47 of 375 (12.5%) patients in GLORIA.
Baseline demographics and disease severity were similar between dosage groups with more men in the high-dosage group.
Compared with the <2000 mg/day dosage group, patients requiring ≥2000 mg/day LCIG had higher rates of AEs/ADRs including polyneuropathy; improvements in “Off” time and discontinuations due to AEs were similar between dosage groups and lower for discontinuations due to ADRs reported in GLORIA.
Conclusions.
Patients who require ≥2000 mg/day LCIG exhibited a safety profile comparable to the established safety/tolerability of LCIG with similar clinical improvements.
Higher AEs were noted but within what is accepted for LCIG.
Continuous administration of LCIG is beneficial to advanced PD patients who require very high doses of levodopa.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zadikoff, Cindy& Poewe, Werner& Boyd, James T.& Bergmann, Lars& Ijacu, Horia& Kukreja, Pavnit…[et al.]. 2020. Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa. Parkinson’s Disease،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1206541
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zadikoff, Cindy…[et al.]. Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa. Parkinson’s Disease No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1206541
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zadikoff, Cindy& Poewe, Werner& Boyd, James T.& Bergmann, Lars& Ijacu, Horia& Kukreja, Pavnit…[et al.]. Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa. Parkinson’s Disease. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1206541
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1206541
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر